Piramal Pharma announced on September 30 that it will invest $80 million to expand its sterile injectables facility in Lexington, Kentucky. The investment, financed through a mix of bank loans and internal funds, aims to boost the facility’s capacity to meet growing demand.
Nandini Piramal, Chairperson of Piramal Pharma, highlighted the strategic significance of this expansion, stating that it will position the Lexington site to capitalize on the rapidly growing injectables market and strengthen its role as a key player in the sector.
The Lexington facility is a sterile injectables specialist with differentiated products in the market. Piramal Pharma, a CDMO, offers end-to-end drug development and manufacturing services.
It also said that the addressable market for its current pipeline of generic injectables is estimated at $2.2 billion. Beyond this, Piramal Pharma had its Ahmedabad manufacturing facility receive an Establishment Inspection Report with zero observations, further reiterating the commitment of the Group to the very finest primes in manufacturing.
Do you have a news tip for Lakshmishree reporters? Please email us at media@lakshmishree.com
Source: Moneycontrol
News Desk
